PTPRD and neoplasm: Although it is possible that patients with specific tumor locations are more likely to harbor PTPRD mutations and could be more likely to be bevacizumab resistant, our cohort only included two patients with splenic flexure tumors, and was therefore not suitable to confirm those results.